+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Interleukin Inhibitors for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, End User, Treatment Line, Patient Severity - Global Forecast 2025-2030- Product Image
Interleukin Inhibitors for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, End User, Treatment Line, Patient Severity - Global Forecast 2025-2030- Product Image
New

Interleukin Inhibitors for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, End User, Treatment Line, Patient Severity - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6135100
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Unveiling the Strategic Framework and Core Objectives Guiding the Comprehensive Exploration of Interleukin Inhibitors in Psoriasis Management

The field of psoriasis management has been fundamentally redefined by the advent of interleukin inhibitors, which target key inflammatory pathways to achieve sustained disease control. Historically, treatment options were limited to broad-spectrum immunosuppressants that often carried significant safety concerns and variable efficacy. As our understanding of cytokine networks deepened, interleukins 12, 17, and 23 emerged as pivotal drivers of psoriatic inflammation. This revelation has catalyzed a shift toward targeted biologics, offering higher response rates and improved patient quality of life.

This report embarks on a comprehensive exploration of these novel therapies, framing the current landscape within a strategic context. It examines clinical trial outcomes, patient adherence patterns, and evolving safety profiles alongside real-world evidence. Additionally, the analysis elucidates market entry dynamics and the competitive environment, identifying critical success factors for stakeholders. By capturing the interplay between scientific breakthroughs and commercial strategies, this introduction lays the groundwork for actionable insights that will guide decision-makers in navigating the complexities of interleukin inhibitors for psoriasis.

Charting the Pivotal Innovations and Disruptive Therapeutic Breakthroughs Shaping the Future Landscape of Interleukin Inhibitor Applications in Psoriasis Care

Recent years have witnessed an unprecedented acceleration in therapeutic innovation within the psoriasis space. Advancements in molecular biology have unveiled distinct interleukin subtypes, enabling the design of monoclonal antibodies with unparalleled selectivity. These breakthroughs have disrupted traditional treatment paradigms by delivering rapid onset of action and durable clearance of lesions. Concurrently, biosimilar entries are stimulating competitive pricing and expanding patient access, while digital health tools are enhancing remote disease monitoring and adherence support.

Moreover, the integration of pharmacogenomics is paving the way for personalized medicine, with emerging biomarkers predicting individual treatment response and safety profiles. Patient advocacy groups and regulatory agencies are collaborating to streamline trial designs and expedite approvals, reflecting a broader shift toward patient-centric development. Collectively, these transformative shifts underscore a dynamic ecosystem where scientific innovation and market forces converge to redefine standards of care.

Exploring the Economic Pressures and Strategic Responses Arising from United States Tariff Adjustments on Interleukin Inhibitor Supply Chains and Access

As the United States prepares to implement new tariff adjustments in 2025, stakeholders in the interleukin inhibitor supply chain must anticipate both direct and indirect economic consequences. Import duties on key biologic components, including monoclonal antibody manufacturing reagents and specialized cell culture media, will elevate production costs for contract manufacturing organizations. These added expenses are expected to cascade downstream, potentially pressuring wholesale pricing structures and reimbursement negotiations with payers.

In response, manufacturers may pursue localized production strategies, establishing domestic fill-finish facilities to mitigate import exposure. Such initiatives could shorten lead times and fortify supply chain resilience, albeit requiring substantial capital investment and regulatory approvals. Meanwhile, strategic collaborations between pharmaceutical companies and local suppliers will become critical to maintaining cost efficiency. By proactively aligning manufacturing footprints with tariff landscapes, industry participants can safeguard margins and ensure uninterrupted patient access to these vital therapies.

Decoding the Diverse Therapeutic Segments and Administration Pathways Shaping the Nuanced Outlook of Interleukin Inhibitor Utilization in Psoriasis Treatment

The market structure for interleukin inhibitors is shaped by multiple therapeutic and delivery dimensions. Interleukin 12/23 inhibitors such as ustekinumab stand alongside interleukin 17 inhibitors, encompassing formulations like brodalumab, ixekizumab, and secukinumab, and interleukin 23 inhibitors including guselkumab, risankizumab, and tildrakizumab, each offering distinct efficacy and safety profiles. Administration routes further segment the market into intravenous infusions and self-administered subcutaneous injections, influencing both patient convenience and healthcare resource utilization.

Distribution pathways range from hospital pharmacies that cater to infusion therapies, to online pharmacies that provide home delivery, and retail outlets that support point-of-care dispensing. End-user landscapes include dermatology clinics where specialized expertise drives prescribing patterns, general hospitals managing complex comorbidities, and specialty clinics offering multidisciplinary care. Treatment lines span first-line protocols for newly diagnosed individuals, refractory regimens addressing treatment failures, and second-line options optimized for partial responders. Patient severity classifications distinguish moderate cases from severe presentations, guiding dosing strategies and monitoring requirements. By interweaving these segmentation layers, the analysis uncovers nuanced adoption trends and strategic imperatives across the therapeutic continuum.

Mapping the Regional Dynamics and Market Drivers across the Americas, Europe Middle-East and Africa, and Asia-Pacific in the Interleukin Inhibitor Domain

Regional dynamics within the interleukin inhibitor domain reflect varying healthcare infrastructures, regulatory environments, and reimbursement frameworks. In the Americas, established biologics markets benefit from progressive payer policies and robust clinical trial networks, driving early adoption and iterative innovation. Patient advocacy efforts further accelerate access through expanded insurance coverage and compassionate use programs.

Within Europe, the Middle East, and Africa, heterogeneity in health system maturity creates pockets of rapid uptake alongside areas constrained by budgetary limitations. Centralized European procurement models and guidelines from regional regulatory bodies streamline market entries, but negotiations on pricing and health technology assessments remain critical. In contrast, emerging economies in the Middle East and Africa prioritize local manufacturing partnerships to improve affordability.

Meanwhile, the Asia-Pacific region exhibits tremendous growth potential, fueled by growing prevalence rates, expanding urban healthcare infrastructure, and increasing awareness of biologic therapies. Government initiatives to enhance healthcare financing and localized clinical research collaborations are contributing to a more favorable environment for interleukin inhibitor adoption. Together, these regional insights illuminate where market entry strategies and investment priorities should be focused to maximize impact.

Uncovering Strategic Collaborations and Competitive Strengths of Leading Biopharma Players in the Development of Interleukin Inhibitors for Psoriasis Care

Leading biopharmaceutical organizations are driving the evolution of interleukin inhibitor therapies through targeted research collaborations, strategic acquisitions, and diversified pipelines. Partnerships between established developers and biotech innovators are accelerating the translation of novel antibody constructs into late-stage clinical trials. Simultaneously, alliances with academic centers are enabling the identification of predictive biomarkers and the refinement of patient stratification models.

Mergers and acquisitions continue to reshape the competitive landscape, as companies seek to bolster their portfolios with complementary assets and expand geographic reach. At the same time, smaller specialty players are leveraging niche expertise to introduce differentiated formulations and delivery devices. Heightened interest in biosimilars is intensifying cost competition, prompting originators to reinforce brand fidelity through real-world evidence generation and value-based contracting. By synthesizing these strategic maneuvers, stakeholders can discern which corporate initiatives are poised to deliver sustainable growth and competitive advantage.

Presenting Actionable Roadmaps to Empower Industry Leaders in Accelerating Patient Outcomes and Commercial Growth with Interleukin Inhibitor Therapies

To capitalize on the burgeoning opportunities within interleukin inhibitor therapeutics, industry leaders should prioritize investments in precision medicine frameworks that integrate biomarker-driven patient selection with adaptive trial designs. This approach enhances clinical success rates and aligns with emerging payer requirements for demonstrable value. In addition, developing robust digital support platforms can bolster adherence and facilitate remote monitoring, thereby improving long-term treatment outcomes.

Strategic expansion of contract manufacturing capabilities, particularly in key regions, will mitigate supply chain vulnerabilities and reduce exposure to tariff fluctuations. Furthermore, forging cross-sector partnerships-spanning diagnostics companies, technology providers, and patient advocacy groups-can create comprehensive care ecosystems that differentiate offerings. Finally, embedding real-world data analytics into lifecycle management plans will support dynamic pricing strategies and evidence generation initiatives, ensuring that product portfolios remain responsive to shifting market demands.

Outlining the Analytical Framework and Data Collection Techniques Employed to Deliver a Comprehensive Market Research Study on Inhibitor Therapies

This research study is grounded in a rigorous analytical framework that synthesizes insights from a multitude of primary and secondary data sources. Primary interviews with KOLs, pharmaceutical executives, and healthcare providers informed qualitative perspectives on clinical differentiation and market access. Simultaneously, secondary research encompassed peer-reviewed publications, regulatory filings, conference presentations, and industry white papers to validate emerging trends and therapeutic mechanisms.

Quantitative data were triangulated through statistical modeling of clinical trial databases and aggregate prescription records, ensuring that findings reflect both experimental and real-world performance. The methodology also integrated scenario analysis to assess the impact of external factors such as policy shifts and tariff implementations. All insights underwent iterative validation cycles with subject matter experts to refine assumptions and corroborate strategic recommendations. This comprehensive approach ensures that the report delivers a reliable foundation for informed decision-making in the interleukin inhibitor domain.

Synthesizing Core Findings and Strategic Imperatives to Illuminate the Future Trajectory of Interleukin Inhibitors in Psoriasis Therapeutic Landscapes

The synthesis of scientific advancements, economic dynamics, and strategic corporate initiatives presented in this report underscores the transformative momentum within the interleukin inhibitor landscape. By targeting specific cytokine pathways, these therapies have transcended the limitations of earlier treatment modalities, offering new hope to patients with moderate to severe psoriasis. Concurrently, evolving regulatory frameworks and market access strategies are shaping cost-effectiveness considerations and influencing adoption curves across regions.

Looking ahead, organizations that effectively integrate precision medicine, supply chain resilience, and digital support platforms will be best positioned to capture value. Collaborative models involving cross-industry partnerships and real-world evidence generation will further elevate standards of care. As interleukin inhibitors continue to mature, sustained innovation and adaptive commercial strategies will determine which stakeholders emerge as category leaders. This conclusion sets the stage for targeted actions that will drive next-generation growth in psoriasis therapeutics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Interleukin 12/23 Inhibitors
      • Ustekinumab
    • Interleukin 17 Inhibitors
      • Brodalumab
      • Ixekizumab
      • Secukinumab
    • Interleukin 23 Inhibitors
      • Guselkumab
      • Risankizumab
      • Tildrakizumab
  • Route Of Administration
    • Intravenous
    • Subcutaneous
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Dermatology Clinics
    • Hospitals
    • Specialty Clinics
  • Treatment Line
    • First Line Treatment
    • Refractory Treatment
    • Second Line Treatment
  • Patient Severity
    • Moderate Psoriasis
    • Severe Psoriasis
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Novartis AG
  • Eli Lilly and Company
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Merck & Co., Inc.
  • Amgen Inc.
  • LEO Pharma A/S

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Real-world analysis of long-term safety and sustained efficacy of anti-IL-23 therapies in moderate-to-severe psoriasis
5.2. Impact of emerging biosimilar IL-17 inhibitors on cost dynamics and payer reimbursement policies in key markets
5.3. Utilization of predictive biomarkers to stratify patient response to different interleukin inhibitor classes in psoriasis
5.4. Market penetration strategies for self-administered autoinjector devices in biologic-naive psoriasis populations
5.5. Comparative head-to-head clinical trial outcomes between IL-17 and IL-23 inhibitors influencing prescribing trends
5.6. Post-pandemic supply chain resilience and manufacturing scale-up for novel interleukin inhibitors across global regions
5.7. Integration of teledermatology platforms to monitor adherence and therapeutic outcomes in patients on IL inhibitors
5.8. Phase 3 pipeline candidates targeting novel interleukin pathways such as IL-36 and IL-22 in refractory psoriasis
5.9. Economic evaluations of cost-effectiveness thresholds for second-generation interleukin inhibitors in Europe and North America
5.10. Competitive landscape shifts following patent expirations of first-generation IL-12/23 inhibitors and biosimilar launches
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Interleukin Inhibitors for Psoriasis Market, by Drug Class
8.1. Introduction
8.2. Interleukin 12/23 Inhibitors
8.2.1. Ustekinumab
8.3. Interleukin 17 Inhibitors
8.3.1. Brodalumab
8.3.2. Ixekizumab
8.3.3. Secukinumab
8.4. Interleukin 23 Inhibitors
8.4.1. Guselkumab
8.4.2. Risankizumab
8.4.3. Tildrakizumab
9. Interleukin Inhibitors for Psoriasis Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
10. Interleukin Inhibitors for Psoriasis Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Interleukin Inhibitors for Psoriasis Market, by End User
11.1. Introduction
11.2. Dermatology Clinics
11.3. Hospitals
11.4. Specialty Clinics
12. Interleukin Inhibitors for Psoriasis Market, by Treatment Line
12.1. Introduction
12.2. First Line Treatment
12.3. Refractory Treatment
12.4. Second Line Treatment
13. Interleukin Inhibitors for Psoriasis Market, by Patient Severity
13.1. Introduction
13.2. Moderate Psoriasis
13.3. Severe Psoriasis
14. Americas Interleukin Inhibitors for Psoriasis Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Interleukin Inhibitors for Psoriasis Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Interleukin Inhibitors for Psoriasis Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Eli Lilly and Company
17.3.3. AbbVie Inc.
17.3.4. Janssen Biotech, Inc.
17.3.5. Merck & Co., Inc.
17.3.6. Amgen Inc.
17.3.7. LEO Pharma A/S
18. ResearchAI19. ResearchStatistics20. ResearchContacts21. ResearchArticles22. Appendix
List of Figures
FIGURE 1. INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET: RESEARCHAI
FIGURE 28. INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET: RESEARCHSTATISTICS
FIGURE 29. INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET: RESEARCHCONTACTS
FIGURE 30. INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY GUSELKUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY GUSELKUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TILDRAKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TILDRAKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY FIRST LINE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY FIRST LINE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY REFRACTORY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY REFRACTORY TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECOND LINE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECOND LINE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY MODERATE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY MODERATE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY SEVERE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY SEVERE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 113. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 116. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 117. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 118. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 119. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 120. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 121. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 128. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 129. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 130. CANADA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 131. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 147. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 148. MEXICO INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 223. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 224. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 225. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 238. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 239. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 240. GERMANY INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 241. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 242. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 243. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 256. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 257. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 258. FRANCE INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT SEVERITY, 2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Interleukin Inhibitors for Psoriasis Market report include:
  • Novartis AG
  • Eli Lilly and Company
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Merck & Co., Inc.
  • Amgen Inc.
  • LEO Pharma A/S

Related Topics

Related Reports

Biologic Medications for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2025-2030 - Product Image

Biologic Medications for Psoriasis Market by Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Systemic Psoriasis Therapeutics - Global Strategic Business Report - Product Image

Systemic Psoriasis Therapeutics - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Interleukin Inhibitors Market Report and Forecast 2024-2032 - Product Image

Interleukin Inhibitors Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Type, Route Of Administration (SC, IV), Application (RA, Psoriasis, IBD, Asthma), End-use, Region, and Segment Forecasts, 2025-2030 - Product Image

Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Type, Route Of Administration (SC, IV), Application (RA, Psoriasis, IBD, Asthma), End-use, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Interleukin Inhibitors - Global Strategic Business Report - Product Image

Interleukin Inhibitors - Global Strategic Business Report

  • Report
  • 288 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.